title: Pegylated interferon treatment of acute pericarditis associated with acute hepatitis C.
abstract: A 65-year-old female patient was admitted to our hospital with the symptoms of chest pain, dyspnea and fatigue. She had undergone a tooth extraction three months before. She took no medication. Echocardiography revealed pericardial effusion. The serum alanine aminotransferase (ALT) at presentation was 650 IU/L and aspartate aminotransferase (AST) was 600 IU/L. Hepatitis C virus (HCV) RNA level was 150,000 IU/ml. Genotype was 1b. Acute pericarditis was considered to be caused by acute HCV infection. The patient was followed without treatment. One month later, AST and ALT were found as 65 IU/L and 82 IU/L, respectively; there were symptoms of effort dyspnea and fatigue. Echocardiography showed minimal decrease in pericardial effusion compared to one month previously. HCV RNA level was again checked and found as 155,000 IU/ml. The patient was given pegylated interferon. One month later, the pericardial effusion and related symptoms had disappeared. The pegylated interferon treatment was sustained for 24 weeks and HCV-RNA was found negative at the 3rd and 6th months of the treatment and six months after the end of treatment. We conclude that pegylated interferon may be offered to patients with symptomatic acute HCV-related pericarditis.
authors: Department of Gastroenterology, Kocaeli University, Medical Faculty, Kocaeli, Turkey. drokocaman@hotmail.com
authors: Orhan
authors: O
authors: Kocaman
authors: Cem
authors: C
authors: Aygün
authors: Tolga
authors: T
authors: Konduk
authors: Altay
authors: A
authors: Celebi
authors: Omer
authors: O
authors: Sentürk
authors: Sadettin
authors: S
authors: Hülagü
mesh_terms: D000208:Acute Disease; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D010493:Pericarditis / Q000188:drug therapy* / Q000821:virology; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a